Literature DB >> 33618754

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.

Musa Yilmaz1, Mansour Alfayez1, Courtney D DiNardo1, Gautam Borthakur1, Tapan M Kadia1, Marina Y Konopleva1, Sanam Loghavi2, Rashmi Kanagal-Shamanna2, Keyur P Patel2, Elias J Jabbour1, Guillermo Garcia-Manero1, Naveen Pemmaraju1, Sherry A Pierce1, Issa Ghayas1, Nicholas J Short1, Guillermo Montalban-Bravo1, Koichi Takahashi1, Rita Assi1, Ahmad S Alotaibi1, Maro Ohanian1, Michael Andreeff1, Jorge E Cortes1, Hagop M Kantarjian1, Farhad Ravandi1, Naval G Daver3.   

Abstract

Entities:  

Year:  2021        PMID： 33618754      PMCID： PMC7901199          DOI： 10.1186/s13045-020-01023-9

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN： 1756-8722            Impact factor:   17.388


× No keyword cloud information.
  15 in total

1.  Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

Authors:  Jorge Cortes; Alexander E Perl; Hartmut Döhner; Hagop Kantarjian; Giovanni Martinelli; Tibor Kovacsovics; Philippe Rousselot; Björn Steffen; Hervé Dombret; Elihu Estey; Stephen Strickland; Jessica K Altman; Claudia D Baldus; Alan Burnett; Alwin Krämer; Nigel Russell; Neil P Shah; Catherine C Smith; Eunice S Wang; Norbert Ifrah; Guy Gammon; Denise Trone; Deborah Lazzaretto; Mark Levis
Journal:  Lancet Oncol       Date:  2018-05-31       Impact factor: 41.316

2.  Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

Authors:  Jorge E Cortes; Hagop Kantarjian; James M Foran; Darejan Ghirdaladze; Mamia Zodelava; Gautam Borthakur; Guy Gammon; Denise Trone; Robert C Armstrong; Joyce James; Mark Levis
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

3.  Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Authors:  Jorge E Cortes; Martin S Tallman; Gary J Schiller; Denise Trone; Guy Gammon; Stuart L Goldberg; Alexander E Perl; Jean-Pierre Marie; Giovanni Martinelli; Hagop M Kantarjian; Mark J Levis
Journal:  Blood       Date:  2018-06-06       Impact factor: 22.113

4.  Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

Authors:  Richard M Stone; Sumithra J Mandrekar; Ben L Sanford; Kristina Laumann; Susan Geyer; Clara D Bloomfield; Christian Thiede; Thomas W Prior; Konstanze Döhner; Guido Marcucci; Francesco Lo-Coco; Rebecca B Klisovic; Andrew Wei; Jorge Sierra; Miguel A Sanz; Joseph M Brandwein; Theo de Witte; Dietger Niederwieser; Frederick R Appelbaum; Bruno C Medeiros; Martin S Tallman; Jürgen Krauter; Richard F Schlenk; Arnold Ganser; Hubert Serve; Gerhard Ehninger; Sergio Amadori; Richard A Larson; Hartmut Döhner
Journal:  N Engl J Med       Date:  2017-06-23       Impact factor: 91.245

5.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

6.  Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

Authors:  Christoph Röllig; Hubert Serve; Andreas Hüttmann; Richard Noppeney; Carsten Müller-Tidow; Utz Krug; Claudia D Baldus; Christian H Brandts; Volker Kunzmann; Hermann Einsele; Alwin Krämer; Kerstin Schäfer-Eckart; Andreas Neubauer; Andreas Burchert; Aristoteles Giagounidis; Stefan W Krause; Andreas Mackensen; Walter Aulitzky; Regina Herbst; Mathias Hänel; Alexander Kiani; Norbert Frickhofen; Johannes Kullmer; Ulrich Kaiser; Hartmut Link; Thomas Geer; Albert Reichle; Christian Junghanß; Roland Repp; Frank Heits; Heinz Dürk; Jana Hase; Ina-Maria Klut; Thomas Illmer; Martin Bornhäuser; Markus Schaich; Stefani Parmentier; Martin Görner; Christian Thiede; Malte von Bonin; Johannes Schetelig; Michael Kramer; Wolfgang E Berdel; Gerhard Ehninger
Journal:  Lancet Oncol       Date:  2015-11-06       Impact factor: 41.316

7.  Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Wui-Jin Koh; Nadeem R Abu-Rustum; Sarah Bean; Kristin Bradley; Susana M Campos; Kathleen R Cho; Hye Sook Chon; Christina Chu; Rachel Clark; David Cohn; Marta Ann Crispens; Shari Damast; Oliver Dorigo; Patricia J Eifel; Christine M Fisher; Peter Frederick; David K Gaffney; Ernest Han; Warner K Huh; John R Lurain; Andrea Mariani; David Mutch; Christa Nagel; Larissa Nekhlyudov; Amanda Nickles Fader; Steven W Remmenga; R Kevin Reynolds; Todd Tillmanns; Stefanie Ueda; Emily Wyse; Catheryn M Yashar; Nicole R McMillian; Jillian L Scavone
Journal:  J Natl Compr Canc Netw       Date:  2019-01       Impact factor: 12.693

8.  Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.

Authors:  Alexander E Perl; Jessica K Altman; Jorge Cortes; Catherine Smith; Mark Litzow; Maria R Baer; David Claxton; Harry P Erba; Stan Gill; Stuart Goldberg; Joseph G Jurcic; Richard A Larson; Chaofeng Liu; Ellen Ritchie; Gary Schiller; Alexander I Spira; Stephen A Strickland; Raoul Tibes; Celalettin Ustun; Eunice S Wang; Robert Stuart; Christoph Röllig; Andreas Neubauer; Giovanni Martinelli; Erkut Bahceci; Mark Levis
Journal:  Lancet Oncol       Date:  2017-06-20       Impact factor: 41.316

Review 9.  Targeting FLT3 mutations in AML: review of current knowledge and evidence.

Authors:  Naval Daver; Richard F Schlenk; Nigel H Russell; Mark J Levis
Journal:  Leukemia       Date:  2019-01-16       Impact factor: 11.528

10.  Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.

Authors:  Musa Yilmaz; Mansour Alfayez; Courtney D DiNardo; Gautam Borthakur; Tapan M Kadia; Marina Y Konopleva; Sanam Loghavi; Rashmi Kanagal-Shamanna; Keyur P Patel; Elias J Jabbour; Guillermo Garcia-Manero; Naveen Pemmaraju; Sherry A Pierce; Issa Ghayas; Nicholas J Short; Guillermo Montalban-Bravo; Koichi Takahashi; Rita Assi; Ahmad S Alotaibi; Maro Ohanian; Michael Andreeff; Jorge E Cortes; Hagop M Kantarjian; Farhad Ravandi; Naval G Daver
Journal:  J Hematol Oncol       Date:  2020-10-08       Impact factor: 17.388
View more
  1 in total

Review 1.  Which FLT3 Inhibitor for Treatment of AML?

Authors:  Jayastu Senapati; Tapan Mahendra Kadia
Journal:  Curr Treat Options Oncol       Date:  2022-03-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.